Celgene Corporation (CELG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
109.90-0.70 (-0.64%)
As of 1:08 PM EDT. Market open.
People also watch:
GILDBIIBREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open110.77
Prev Close110.60
Bid109.88 x 100
Ask109.90 x 200
Day's Range108.66 - 111.00
52wk Range93.05 - 128.39
1y Target EstN/A
Market Cap85.18B
P/E Ratio (ttm)46.45
Beta1.46
Volume2,302,450
Avg Vol (3m)4,503,971
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Barrons.com3 hours ago

    Biotech Stocks: Oops, She Did It Again

    Yesterday, biotech stocks--including BioMarin Pharmaceutical (BMRN), Tesaro (TSRO), Vertex Pharmaceuticals (VRTX) and Celgene (CELG)--got pounded after Hillary Clinton tweeted that there was "no justification" for EpiPen price hikes, echoing what happened back in September 2015. RBC's Michael Yee and team consider the implications: The SPDR S&P Biotech index was down -4.3% today (vs SPX down -0.5%) and was one of the sharpest daily moves down in 8 weeks (i.e., Brexit) - but importantly, is after an already large +25% move since the Brexit bottom. Importantly, the sharp pullback was due mostly in our view to investor fear of more political risk around drug pricing concerns and potential changes in the future after Hillary Clinton tweeted "EpiPens can be the difference between life and death.

  • 24/7 Wall St.4 hours ago

    Short Sellers Increase Bets in Major Biotechs

    The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.

  • Dear Pfizer, Stop Overpaying for Acquisitions!
    Motley Fool21 hours ago

    Dear Pfizer, Stop Overpaying for Acquisitions!

    M&A is a big part of Pfizer's growth strategy, but the company hasn't done a very good job of reasonably pricing its purchases.